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FOREWORD 
TB remains a major health problem globally, in the U.S. and in 
Iowa, killing an estimated 1.3 million people annually.  
Despite this grim statistic, TB morbidity rates are declining in 
the U.S. and around the world.  In Iowa, TB case rates remain 
relatively stable due to the influx of immigrants and refugees 
from areas of the world where TB is prevalent.  Vigilance is 
required to properly treat and cure patients to prevent 
treatment relapse, treatment failure or the development of 
acquired drug resistant TB.  Declines in funding, misdiagnosis 
and challenging clinical case management still plague TB 
Control efforts in the United States.   
PURPOSE AND OVERVIEW 
The purpose of this report is to provide a summary of 
Tuberculosis (TB) in Iowa and the activities and achievements 
of the TB Control Program and our partners during the 2014 
calendar year.  This report provides Iowa-specific TB rates, 
funding sources, and program-specific data, often in ten-year 
time lines to more accurately reflect trends.    
Previous reports included TB control efforts by the World 
Health Organization and the Centers for Disease Control and 
Prevention.  Reports paid tribute to the role TB disease 
played in the history of man including historical TB 
treatments, myths, and bygone TB control practices.  The 
2014 Report does not include these overviews.  Please refer 
to previous reports for this information.   
The annual report serves as an informational resource for 
stakeholders, local partners, policy makers and others 
interested in Iowa’s TB Control efforts.  The report is available 
for download on the TB Control Program Web page 
http://www.idph.state.ia.us/ImmTB/TB.aspx?prog=Tb&pg=Tb
Home. 
IOWA’S TB CONTROL PROGRAM 
The TB Program is comprised of two full time employees:  the 
Program Manager and the TB Nurse Consultant.  The program 
provides direct oversight of cases afflicted with latent 
tuberculosis infection (LTBI) and TB disease from admission to 
discharge in the TB Control Program.  This includes 
consultation with physicians, nurses, local public health 
agencies (LPHAs) and other healthcare providers regarding TB 
transmission, pathogenesis, treatment, signs and symptoms, 
infection control practices, and contact investigations.   
The purpose and scope of responsibilities is defined by the 
core functions of the TB Control Program which include: 
• Disease consultation and education 
• Investigation of active or suspect TB cases 
• Case management of LTBI and active TB cases 
• Administration of Iowa’s TB Medication Program  
• Data management and analysis 
• Administration and finance 
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THE DIFFERENCE BETWEEN LATENT TB 
INFECTION AND TB DISEASE: 
FROM CDC’S DIVISION OF TB ELIMINATION 
WHAT IS TB?  
Tuberculosis (TB) is a disease caused by a germ called 
Mycobacterium tuberculosis that is spread from person to 
person through the air.  
 
  
TB usually affects the lungs, but it can also affect other parts 
of the body, such as the brain, the kidneys, or the spine.  
When a person with infectious TB coughs or sneezes, droplet 
nuclei containing M. tuberculosis are expelled into the air.  If 
another person inhales air containing these droplet nuclei, he 
or she may become infected.  However, not everyone 
infected with TB bacteria becomes sick.  As a result, two TB-
related conditions exist: latent TB infection and TB disease. 
WHAT IS LATENT TB INFECTION? 
Persons with latent TB infection do not feel sick and do not 
have any symptoms.  They are infected with M. tuberculosis, 
but do not have TB disease.  The only sign of TB infection is a 
positive reaction to the tuberculin skin test or TB blood test.  
Persons with latent TB infection are not infectious and 
cannot spread TB infection to others. 
 
LTBI Characteristics 
• Usually has a skin test or blood test result 
indicating TB infection 
• Has a normal chest x-ray and a negative sputum 
test 
• Has TB bacteria in his/her body that are alive, but 
inactive 
• Does not feel sick 
• Cannot spread TB bacteria to others  
• Needs treatment for latent TB infection to prevent 
TB disease; however, if exposed and infected by a 
person with multidrug-resistant TB (MDR TB) or 
extensively drug-resistant TB (XDR TB), preventive 
treatment may not be an option 
Without treatment, about 5 to 10% of infected persons will 
develop TB disease at some time in their lives.  About half of 
those people who develop TB will do so within the first two 
years of infection.  For persons whose immune systems are 
weak, especially those with HIV infection, the risk of 
developing TB disease is considerably higher than for persons 
with normal immune systems. 
Of special concern are persons infected by someone with 
extensively drug-resistant TB (XDR TB) who later develops TB 
disease; these persons will have XDR TB, not regular TB 
disease. 
WHAT IS TB DISEASE? 
In some people, TB bacteria overcome the defenses of the 
immune system and begin to multiply, resulting in the 
progression from latent TB infection to TB disease.  Some 
people develop TB disease soon after infection, while others 
develop TB disease later when their immune system becomes 
weak.  The general symptoms of TB disease include:  
• Unexplained weight loss 
• Loss of appetite 
• Night sweats 
• Fever 
• Fatigue 
• Chills 
The symptoms of TB of the lungs include: 
• Coughing for 3 weeks or longer 
• Hemoptysis (coughing up blood) 
• Chest pain 
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Other symptoms depend on the part of the body that is 
affected.  Persons with TB disease are considered infectious 
and may spread TB bacteria to others.  If TB disease is 
suspected, persons should be referred for a complete medical 
evaluation.  If it is determined that a person has TB disease, 
therapy is given to treat it.  TB disease is a serious condition 
and can lead to death if not treated. 
TB Disease Characteristics 
• Usually has a skin test or blood test result 
indicating TB infection 
• May have an abnormal chest x-ray, or positive 
sputum smear or culture 
• Has TB bacteria in his/her body 
• Usually feels sick and may have symptoms such 
as coughing, fever, and weight loss 
• May spread TB bacteria to others 
• Needs medication to treat TB disease 
 
TB MORBIDITY AND TRENDS IN IOWA 
The number of TB cases in Iowa, as in the rest of the U.S., has 
significantly declined since the discovery of antibiotics that 
kill the TB bacilli.  Despite drugs that can cure TB disease, TB 
remains a significant public health issue in Iowa and the rest 
of the country.  The 2014 TB case rate for Iowa is 1.75 cases 
per 100,000 persons.  This is significantly lower than the 2014 
national average of 3.0 cases per 100,000 persons.  Iowa 
owes its low TB case rate in part to proficient contact 
investigations, healthcare providers observance of treatment 
guidelines, adherence to DOT for active disease cases and the 
provision of medication for LTBI to approximately a thousand 
Iowan’s annually. 
During the last decade, Iowa averaged greater than 1,200 
LTBI and 46 TB disease cases each year.  Figure 1 illustrates 
the average number of cases in Iowa each year by decade, 
dating back to 1930.  Note that Iowa averaged 757 cases of 
TB disease each year during the decade of the 1940s.  During 
this decade, scientist first discovered antibiotics that could 
treat TB, culminating with the discovery of other antibiotics in 
the 50’s and 60’s that led to doctors curing patients of TB.  
The discovery and use of these antibiotics ultimately led to 
the sharp decline of TB cases and subsequently, the number 
of persons with LTBI.  Persons with untreated LTBI represent 
the reservoir of future TB cases.    
 
 
Figure 1: Average Number of TB Cases in Iowa Each Year - by 
Decade.  
In 2014, Iowa reported 54 cases of active TB disease.  Since 
2005, Iowa has averaged 46 cases of TB each year.  (Figure 2:  
Number of TB cases 2005 - 2014).  Although case rates are 
declining, many cases have existing co-morbidities that make 
TB treatment considerably more complex and require 
extensive care, including the use of second line drugs.  
Treatment with second line drugs is complicated and 
expensive, requiring expert consultation and extended 
treatment durations.  
 
 
Figure 2: Number of Iowa TB Cases per Year 2005-2014 
  
Counties with larger population centers such as Polk, Black 
Hawk and Johnson report the majority of TB cases.  However, 
as Figure 3 illustrates, many (52/99) Iowa counties reported 
TB cases during calendar years 2005 - 2014.
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Figure 3: Iowa Counties with TB Cases 2005 - 2014 
LTBI AND TB DISEASE TREATMENT 
The program prioritizes the detection and treatment of 
persons with LTBI to prevent future cases of TB disease.  
Figure 4 illustrates that the Program issues greater than 1,200 
LTBI prescriptions on average each year to Iowan’s diagnosed 
with LTBI.  Left untreated, 5-10% of persons with LTBI will 
develop TB disease.  The only way to eliminate TB disease is 
to treat and cure all persons diagnosed with LTBI. 
 
Figure 4: Number of LTBI cases each year from 2005 – 2014 
The length of LTBI treatment (up to nine months) coupled 
with a lack of public health resources, results in patients 
having to complete LTBI treatment on their own accord, just 
like with other illnesses.  Significantly shorter treatment 
regimens paired with public health monitoring is the only 
method that will achieve TB elimination. 
Figure 5 represents the percentage of patients who 
completed treatment from 2004 - 2013.  During this period, 
all patients with infectious TB completed treatment.  
Patient’s not completing treatment had extrapulmonary TB, 
were not infectious and did not represent a public health risk. 
 
Figure 5: Percentage of Iowa TB Cases who Complete Therapy 2004-
2013 
 
It is very important that people who have TB disease finish 
the medicine, taking the drugs exactly as prescribed.  If they 
stop taking the drugs too soon, they can become sick again; if 
they do not take the drugs correctly, the TB bacteria that are 
still alive may become resistant to those drugs.  TB that is 
resistant to drugs is harder and more expensive to treat. 
DIRECTLY OBSERVED THERAPY (DOT) 
DOT is a strategy used by public health officials to assure 
patients with TB disease are correctly treated and cured.  
DOT is the standard of care for all patients afflicted with TB 
disease.  The Centers for Disease Control and Prevention 
(CDC), Infectious Diseases Society of America (IDS), World 
Health Organization (WHO), and the American Thoracic 
Society (ATS) recommend healthcare providers implement 
DOT on each case of TB disease.  With DOT, a designated 
healthcare worker watches a patient swallow each dose of TB 
medication.  Without DOT, many patients do not take their 
medication properly, resulting in disease relapse, treatment 
failure and development of drug resistance, including 
multidrug-resistant TB (MDR-TB).   
In 2001, the Iowa TB Control Program began providing DOT 
incentive funds to increase the proportion of TB patients who 
receive DOT.  Since implementation of incentive funding, DOT 
rates have risen 40% in Iowa.  During this time-period, 
virtually all pulmonary (infectious) cases of TB have had the 
benefit of DOT.  Clinical benefits of DOT include significant 
reduction in disease relapse, treatment failure and 
development of multidrug-resistant TB (MDR-TB). 
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Tuberculosis Cases by County of Residence
Iowa, 2005 - 2014
Total Cases = 464
Source:  Iowa Department of Public Health, TB Control Program
27
1
104
4 1 3 5
20
4
39 121
37
1
18
9 1
1 18
1 2
4 1 3
11 2 1 1 39
11
7 1 3 2
10
2 1 14 27 2 7
2
2
11
2
1
2
3
2
1
7  
 
COUNTRY OF ORIGIN DATA  
The proportion of reported TB cases in non-U.S. born persons 
has increased significantly in the past two decades.  In 1995 
for example, non-U.S. born persons accounted for 38% of 
reported TB cases in Iowa.  From 2005 - 2014, non-U.S. born 
persons accounted for 68% of reported TB cases in Iowa.  
Non-U.S. born persons account for only four percent of the 
Iowa population, highlighting the disparity.  The decreasing 
numbers of U.S. born cases are due in part to effective TB 
control practices in this country.  
 
Figure 6: Percent of U.S. born Versus Non-U.S born TB cases in 
Iowa 2005 - 2014 
In many parts of the developing world, TB is still widespread 
and remains a leading cause of death.  Immigration of people 
from these countries to the United States illustrates what 
happens in one part of the world, directly impacts other parts 
of the world.  Effective targeted testing programs for newly 
arriving refugees, immigrants, and students play a major role 
to identify and treat these populations. 
From 2005 - 2014, 314 individuals, emigrating from 48 
countries (excludes U.S.) developed TB disease after their 
arrival to Iowa (Figure 8).  India and Mexico account for 30% 
of the TB morbidity in Iowa during this time period.  As the 
map illustrates, TB anywhere is TB everywhere.  
Approximately 95% of all patients with active TB disease live 
in the developing world, where 99% of all TB deaths 
occur.  TB is a good example of the global nature of public 
health.  It is important to implement consistent and 
aggressive public health measures to halt TB disease, which 
left untreated, kills half of its victims. 
 
 
 
Figure 7: Country of Origin by Global Representation: Iowa 2005-
2014 
 
In Iowa, eight countries, led by India and Mexico, account for 
198/314 (63%) non U.S. born TB cases from 2005 – 2014 
(figure 8).  Forty other countries complete the TB morbidity, 
further illustrating the global burden of TB. 
 
 
Figure 8: Iowa TB Cases by Country of Origin 2005-2014 
SITE OF DISEASE 
The lungs are the most common site for TB disease, but any 
organ or body site may be involved.  TB of the pleura (lining 
of the lungs) and lymph nodes is the most commonly 
occurring form of extrapulmonary tuberculosis.  In Iowa, 
pulmonary cases accounted for 68% of the total cases during 
the last ten years (Figure 9).  Patients with either pulmonary 
(lungs) or laryngeal (throat) TB are usually infectious.   
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Figure 9: Iowa TB Cases by Site of Disease 2005-2014 
CONTACT INVESTIGATIONS 
All infectious cases require a contact investigation by a LPHA 
to identify contacts who: 
• Have LTBI so treatment for LTBI can be given and 
active disease can be prevented.  
• Have TB disease so they may be treated and further 
transmission can be stopped. 
 
TB Contact Investigations, Iowa 2004-2013 
Cases for investigation:  249 
Number of contacts identified:  4,904 
Number of contacts who completed evaluation:  4,210 (86%) 
Number of LTBI identified:  822 (20%) 
Number of TB cases identified:  25 (<1%) 
Figure 10: Contact Investigation Data 
Each infectious TB case in the United States has 10 contacts 
identified on average per CDC.  Approximately, 20 - 30% of all 
contacts have LTBI, and 1% has TB disease.  Of those contacts 
that ultimately will have TB disease, approximately half 
acquire disease in the first year after exposure.  For this 
reason, contact investigations constitute a crucial prevention 
strategy.  
LPHAs in Iowa are responsible for conducting investigations 
of infectious TB.  Public Health agencies work closely with 
other agencies (e.g., Community Health Centers, private 
providers, labs etc.) to ensure the prompt reporting of 
suspected TB cases.  A major challenge for LPHAs is the time 
involved to complete contact investigations.  In order to be 
considered “evaluated”, contacts to infectious TB cases must 
complete all TB testing, often requiring two TB tests.  Persons 
with positive tests require a medical evaluation to include a 
chest x-ray to rule out active TB.  LPHAs spend considerable 
amounts of resources in their efforts to complete the 
evaluation of contacts exposed to infectious TB. 
The TB Control Program Manager and TB Nurse Consultant 
provide consultation to LPHAs on each infectious case of TB.  
Consultation consists of: 
• When to initiate a contact investigation 
• Assigning priorities to contacts 
• Diagnostic and public health evaluation of contacts 
• When to expand a contact investigation, and  
• Data management of contact investigations 
Contact investigations are timely, costly and consume limited 
resources from local, state and federal assets.  “Contact 
investigations typically require hundreds of interdependent 
decisions, the majority of which are made on the basis of 
incomplete data, and dozens of time consuming 
interventions.”1  For these reasons, consultation and 
collaboration among LPHAs and the TB Program is vital to the 
diagnostic and public health evaluation of contacts.  
  
                                                                
1 Guidelines for the Investigation of Contacts of Persons with Infectious TB – 
Recommendations from the National TB Controllers Association and CDC. 
62% 
32% 
6% 
TB Cases by Site of Disease 
Iowa: 2005 - 2014 
Pulmonary
Extrapulmonary
Both
9  
 
TB CONTROL PROGRAM FUNDING 
In  2014, the TB Control Program received funds from the 
federal TB Cooperative Grant and state funds totaling 
$519,034.  Federal funds comprise 76% of the total budget 
while state funds comprise 24% of the program finances 
(Figure 11).  
Funding Source   2014 
Federal TB Cooperative Grant $391,920 
State Prescription Services $70,670 
State TB  $56,444 
Total $519,034 
Figure 11:   2014 total program funds 
Program expenditures are divided into three main categories:  
program infrastructure (staff salary and operating expenses), 
contracts (including incentive funding for LPHAs to conduct 
directly observed therapy, pharmacy for prescription services 
and the State Hygienic lab), and TB medications.  The funding 
distributions for these three categories are illustrated in 
Figure 12. 
 
Figure 12: 2014 total program funds by funding source 
Figure 13 illustrates how the TB Program disperses available 
contractual funds.  LPHAs receive incentive funding for DOT 
and medical evaluation services.  Funds for pharmacy services 
support the distribution of free antibiotics for all Iowans with 
LTBI or TB disease.  Funds for the State Hygienic Lab support 
rapid identification of TB, smear, culture and drug sensitivity 
testing.   
 
Figure 13:   2014 total funds distribution 
CONTRACT SERVICES 
STATE HYGIENIC LAB  
The TB Control Program contracts with the State Hygienic Lab 
(SHL) through the Tuberculosis Elimination Cooperative 
Agreement.  In 2014, the TB Control Program contract 
amount with SHL was $72,042 as demonstrated in figure 13.  
This agreement allows SHL to be the primary source for public 
health submission of suspect TB patient’s specimens (typically 
sputum) for evaluation.  The goal of SHL is to provide 
objective information within 24 - 48 hours of specimen 
receipt for smear and TB NAAT (rapid detection of MTB 
complex as well as rifampin drug resistance).  SHL works with 
CDC to transfer clinical specimens of patients for whom 
second line drug testing is necessary.  Additionally, SHL 
coordinates genetic testing of all culture positive MTB 
specimens with CDC to allow genetic linking of cases 
nationwide.  The ability to rapidly and accurately detect drug 
resistance in Mycobacterium tuberculosis Complex (MTBC) 
clinical isolates is critical for the appropriate treatment of 
patients suffering from TB and the effectiveness of the TB 
Control program.   
SHL also is one of the few labs in the state that performs 
Interferon-Gamma Release Assays (IGRAs).  IGRAs are whole-
blood tests that can aid in diagnosing TB infection.  SHL offers 
two IGRAs that have been approved by the U.S. Food and 
Drug Administration (FDA) and are commercially available in 
the U.S:  QuantiFERON TB Gold In-Tube test (QFT-GIT); and T-
SPOT® TB test (T-Spot).  IGRAs are of particular use to LPHAs 
in the course of a contact investigation to an infectious TB 
patient.  In a contact investigation, IGRAS are offered to Iowa 
citizens free of charge through the SHL.   
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PHARMACY SERVICES 
The TB Program contracts with NJL Pharmacy of Pleasant Hill, 
Iowa to dispense TB medications for both LTBI and active TB 
disease patients.  In 2014, the TB Control Program spent 
$64,620 on TB medications for Iowa citizens (Figure 12).  The 
contract for pharmacy services is $34,500 as demonstrated in 
Figure 13.    
LOCAL PUBLIC HEALTH AGENCIES 
Iowa is unique in its ability and desire to provide incentive 
funding for LPHA’s who provide directly observed therapy 
(DOT) to active pulmonary patients in their county.  DOT is a 
standard of care for TB in which patients are observed to 
ingest each dose of anti-tuberculosis medications, to 
maximize the likelihood of completion of therapy.  Programs 
utilizing DOT as the central element in a comprehensive, 
patient-centered approach to case management (enhanced 
DOT) have higher rates of treatment completion than less 
intensive strategies.   
The CDC, American Thoracic Society (ATS) and Infectious 
Disease Society of America (IDSA) all recommend healthcare 
providers implement DOT on each active case of TB.  
Eligibility of LPHAs for DOT incentive funding may vary by 
funding cycle due to funding availability and the number of 
TB cases; but generally, all infectious (pulmonary and 
laryngeal), pleural, HIV positive, and childhood cases of TB 
disease are eligible.  In 2014, the Iowa TB Control Program 
spent $49,764 on contracts with LPHAs for DOT services as 
shown in Figure 13.   
 
CONCLUSION 
The TB Program’s vision is Iowans living in communities free of TB disease.  TB disease is both preventable and curable if 
treated early in the disease process.  Iowa health care providers are at the forefront of this vision when they ‘think TB’ and 
diagnose TB early, which not only leads to an early cure, but stops transmission to others.  Local public health agencies 
ensure the cure with the time intensive practice of directly observed therapy, watching their patients swallow each dose of 
medication.  This proven TB control strategy ensures not only the cure, but prevents the development of acquired drug 
resistant TB, treatment relapse, treatment failure and death.  These public health stewards stop further transmission by 
identifying and treating exposed contacts to infectious TB. 
 
The fact remains that untreated, TB disease still kills 50% of its victims and is easily transmitted.  Left unchecked, TB spreads 
through communities with cost measured in dollars and lives.  The medical case management of TB is often complicated.  
Adherence to treatment guidelines is paramount to curing TB.  The TB Control Program is dedicated to eradicating TB in 
Iowa by ensuring each patient with LTBI or TB disease receives the best care available.  The history of TB is as long as the 
history of mankind.  This history has taught us many lessons, both through failures and successes.  It is a lesson that needs 
constant vigilance in order to advance to the final eradication of an ancient disease that is believed to have killed more 
humans throughout history than all other disease combined.   
